FDA tweaks Aduhelm’s label, narrows use of the Biogen drug to mild Alzheimer’s

July 8, 2021 Auto Bot Aduhelm, Biogen, BioPharma, biopharma nl, Cambridge, FDA, Massachusetts, Pharma 0

Dementia or brain damage and injury as a mental health and neurology medical symbol with a thinking human organ made of crumpled paper torn in pieces as a creative concept for alzheimer disease.

The drug label for Biogen Alzheimer’s disease drug Aduhelm has been revised to clarify that its use is for patients with mild forms of the neurodegenerative disorder. The change aligns the prescribing information with the patient population studied in clinical trials.